D
Molecular Partners AG MOLN
$4.61 -$0.05-0.97% NASDAQ
Recommendation
Dividend Power Score
Prev Close
$4.65
Volume
918
Avg Vol (90D)
5,587
Market Cap
$171.39M
Dividend & Yield
--
52-Week Range
$3.36 - $5.10
P/E (TTM)
--
EPS (TTM)
-$1.91
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 - Slideshow
2/4/2026 - SeekingAlpha
Molecular Partners AG (MOLN, $4.57) price may drop as it broke higher Bollinger Band on Feb 02, 2026
2/3/2026 - Tickeron - Stocks
Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript
2/2/2026 - SeekingAlpha
Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript
2/2/2026 - Seeking Alpha: Transcripts
Molecular Partners Highlights Favorable MP0712 DLL3 Radiotherapeutic Imaging, U.S. Phase I/II Ready
2/2/2026 - MarketBeat
Molecular Partners presents first imaging, dosimetry data of MP0712
2/2/2026 - The Fly
Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026
2/2/2026 - Globe Newswire
Brokers Offer Predictions for MOLN FY2025 Earnings
1/29/2026 - MarketBeat
What is HC Wainwright's Estimate for MOLN Q1 Earnings?
1/28/2026 - MarketBeat
HC Wainwright Upgrades Molecular Partners (NASDAQ:MOLN) to "Strong-Buy"
1/28/2026 - MarketBeat
Molecular Partners initiated with a Buy at H.C. Wainwright
1/27/2026 - TipRanks Financial Blog
Molecular Partners initiated with bullish view at H.C. Wainwright, here's why
1/27/2026 - The Fly
Molecular Partners initiated with bullish view at H.C. Wainwright, here's why
1/27/2026 - The Fly
Molecular Partners AG (MOLN, $4.05) Stochastic Oscillator left the oversold zone on January 20, 2026
1/21/2026 - Tickeron - Stocks
Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
1/19/2026 - SeekingAlpha
Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 17.9% in December
1/19/2026 - Ticker Report
Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 17.9% in December
1/19/2026 - MarketBeat
Molecular Partners AG (MOLN, $4.2) price exceeded its 50-day Moving Average on January 16, 2026
1/17/2026 - Tickeron - Stocks
Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
1/15/2026 - SeekingAlpha
Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
1/15/2026 - Seeking Alpha: Transcripts
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th ...
1/11/2026 - GuruFocus
Molecular Partners provided update on latest progress, 2026 milestones
1/11/2026 - TipRanks Financial Blog
Molecular Partners provided update on latest progress, 2026 milestones
1/11/2026 - The Fly
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th ...
1/11/2026 - GuruFocus
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference
1/11/2026 - Globe Newswire
Income Statement
Total Revenue (TTM)
$0.00
EBITDA (TTM)
-$65.31M
EBIT (TTM)
-$67.54M
Net Income (TTM)
-$70.97M
Balance Sheet
Total Assets (Q)
$140.65M
Total Debt (Q)
$1.92M
Total Liabilities (Q)
$20.84M
Book Value Per Share (Q)
$3.20
Cash Flow
Cash from Operations (TTM)
-$62.31M
Cash from Investing (TTM)
$65.25M
Cash from Financing (TTM)
$16.41M
Net Change in Cash (TTM)
$18.54M
Filings
Filing Date
Thursday, October 30, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 2 and 6 (est)
Price History
Loading...
Beta
1.77
7-Day Total Return
4.66%
30-Day Total Return
5.65%
60-Day Total Return
8.10%
90-Day Total Return
22.80%
Year to Date Total Return
9.12%
1-Year Total Return
-6.40%
2-Year Total Return
2.68%
3-Year Total Return
-30.96%
5-Year Total Return
--
52-week Low
Apr 29, 2025 - $3.36
52-week High
Mar 07, 2025 - $5.10
Valuation
Market Cap
$171.39M - Micro Cap
Enterprise Value
$37.88M
Price/Sales (TTM)
--
Price/Book (Q)
1.45
Dividends and Shares
Shares Outstanding
37.40M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.molecularpartners.com
Phone Number
41 44 755 77 00
Address
Wagistrasse 14
Schlieren, 8952
Country
Switzerland
Year Founded
2004
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its... more
NASDAQ 02/13/2026 3:45PM Eastern Quotes delayed